About Prevtec Microbia

Prevtec Microbia is a Canadian biotechnology company specialized in the development of vaccines and other technologies that help fight against bacterial diseases in food animals. In a world where antibiotic use in animal production is increasingly controlled, we develop innovative alternatives to antibiotics. Our products represent sustainable solutions. Prevtec Microbia is an innovation-centric company that operates in many areas of the world through strategic alliances, particularly in Canada and Europe. Prevtec Microbia is proud to be part of the quest for better ways to feed the world.
$33 billion

Estimated value of the global animal health industry by 2020*

* Vetnosis

33

Number of countries where Coliprotec® F4 is approved for use

10+

We have been devising innovative solutions to challenges in livestock production for over a decade.

News
Prevtec Microbia submits dossier to European regulatory authorities for the approval of its Coliprotec® F4/F18 vaccine
20160218
regulatory

Prevtec Microbia is proud to announce that it recently submitted a dossier to the European regulatory authorities, for the approval of its Coliprotec® F4/F18. This live bacterial vaccine for oral administration will offer a broader spectrum than the Coliprotec F4 vaccine presently available in the European Union. It will allow for the immunization of pigs against both E. coli enterotoxinogenic F4 and E. coli enterotoxinogenic F18 bacteria associated with post-weaning diarrhea in swine. Coliprotec F4/F18 will therefore contribute to the reduction of antibiotic use in European swine operations.

 

Prevtec Microbia’s scientific and regulatory team has successfully managed this filing and takes this opportunity to underscore the support of its partners, Elanco and Klifovet in making this project successful.

+
Prevtec Microbia will present at the European Animal Health Forum
20160122
media

Prevtec Microbia was selected as one of twelve emerging animal health companies to present at the first European Animal Health Investment Forum, taking place February 10-11, 2016 at the Royal Garden Hotel in London, UK.

+
  •  

    Antimicrobial resistance (AMR) is resistance of a microorganism to an antimicrobial medicine to which it was originally sensitive. AMR occurs naturally but the phenomenon is hugely increased by excessive and inappropriate use of antimicrobial medicines and poor infection control practices in animals and humans.

     

     

    Source: European Commission, http://europa.eu/rapid/press-release_STATEMENT-15-6097_en.htm